|
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Clinical research trials and YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "Y" Clinical Trials Conditions > YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
For Condition: Hormone-Refractory Prostate Cancer,Prostatic Neoplasms
Status: Terminated
Sponsor(s): Yamanouchi Pharma America ,
Synopsis: The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria:
Total Enrollment:
Location and Contact Information:
Southern Medical Day Care Centre
Wollongong, ,
Australia
Department of Urological Research, Derriford Hospital
Devon, ,
United Kingdom
University of Chicago, Section of Hematology/Oncology
Chicago, Illinois,
United States
Michiana Hematology/Oncology
South Bend, Indiana,
United States
Henry Ford Hospital
Detroit, Michigan,
United States
Hospital Clinic i Provincial, Servicio de Oncologia
Barcelona, ,
Spain
University of Illinois, Department of Urology
Chicago, Illinois,
United States
Dept Urology University of Essen
ESSEN, ,
Germany
Shands Hospital
Gainesville, Florida,
United States
Klinika Nowotworow Ukladu
Warszawa, ,
Poland
Department of Medical Oncology, Concord Hospital Medical Centre
Concord, ,
Australia
Imperial College School of Medicine, Dept Cancer Medicine
London, ,
United Kingdom
Urologische Klinik der MHH
Hannover, ,
Germany
Universitair Medisch Centrum Utrecht, Dienst Medische Oncologie
Utrecht, ,
Netherlands
Hospital Universitario PrĂncipe de Asturias, Servicio de UrologĂa
Madrid, ,
Spain
Krankenhause am Urban, Urologie Dieffenfachstr
Berlin, ,
Germany
Cancer Care Centre, St. George Hospital
Sydney, ,
Australia
Klinikum Mannheim Urology
Mannheim, ,
Germany
Hospital General Vall d'Hebron, Servicio de OncologĂa
Barcelona, ,
Spain
Oddzial Chemioterapii
Krakow, ,
Poland
Szpital CSK WAMl, Klinika Okologii
Warsaw, ,
Poland
Sylvester Comprehensive Cancer Center
Miami, Florida,
United States
Centre Paul Papin
Angers, ,
France
Cliniques Universitaires St-Luc, Service d'Urologie
BRUXELLES, ,
Belgium
Washington University School of Medicine
St. Louis, Missouri,
United States
San Bernardino Urological Associates
San Bernardino, California,
United States
Szpital Wojewodzki im Sw Lukasza SP ZOZ Tarnow
Tarnow, ,
Poland
Service d' Urologie CHU, Hopital Bichat
Paris, ,
France
Department of Medical Oncology, The Canberra Hospital
Canberra, ,
Australia
Department of Urology, St Bartholomew's Hospital
London, ,
United Kingdom
Department of Medical Oncology, Newcastle Mater Hospital
Waratah, ,
Australia
Western Clinical Research, Inc.
Torrance, California,
United States
Kilinika Chemioterapii, Centrum Onkologii Instytut im M sklodowskiej Curie
Krakow, ,
Poland
St Richard's Hospital
West Sussex, ,
United Kingdom
Instituto Valenciano de Oncologia, Servicio de Oncologia
Valencia, ,
Spain
Royal Surrey County Hospital
Surrey, ,
United Kingdom
The Urologic Institute of New Orleans
Gretna, Louisiana,
United States
Georgia Urology,PA Research Institute
Atlanta, Georgia,
United States
Pavillon V, Service d'Urologie et de transplatation, HĂ´pital Edouard Herriot
Lyon, ,
France
Samodzielny Publiczny Zaklad Opieki zdrowotnej, Wojewodzki Osrodek Onkologii
Opole, ,
Poland
Klinika Chemioterapii AM
Lodz, ,
Poland
Queen Elizabeth Hospital, Clinical Hematology & Oncology
Woodville, ,
Australia
Mater Misericordiae Hospital
Dublin, ,
Ireland
Memphis Cancer Center
Memphis, Tennessee,
United States
Centre Hospitalier Notre Dame et Reine Fabiola, Service d'oncologie
Charleroi, ,
Belgium
Service d'Urologie, HĂ´pital Henri Mondor
Creteil, ,
France
Hospital Universitario de Getafe, Servicio de Urologia, Crta
Getafe (Madrid), ,
Spain
Department of Urology, East Surrey Hospital
Surrey, ,
United Kingdom
Clinical Research Centre, St George's Hospital, Urology Division
London, ,
United Kingdom
Department of Clinical Oncology, Royal North Shore Hospital
St. Leonards, ,
Australia
Alaska Clinical Research Center, LLC
Anchorage, Alaska,
United States
Division of Oncology Ward, Royal Brisbane Hospital
HERSTON, ,
Australia
Virginia Mason Medical Center
Seattle, Washington,
United States
Additional Information:
Study ID Numbers: 598-CL-008;
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048659
Other Hormone-Refractory Prostate Cancer Studies:
1. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
2. Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
Related Studies:
Other Hormone-Refractory Prostate Cancer Clinical Trials
Other Clinical Trials
Other Madrid Clinical Trials
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
|
|
|
|
|
|
|
|